Home > Resources > Whitepapers > Multi-Specific Monoclonal Antibodies

Cell and Gene Therapy, MedTech

Multi-Specific Monoclonal Antibodies

February 22, 2023

Multi-Specific Monoclonal
The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

I'm For Real

Enter your details once to access all our information and resources

Spotlight

Adfinitas Health

Adfinitas Health (formerly MDICS) is the trusted partner of more than 50 healthcare systems, hospitals, and post-acute care centers in the Mid-Atlantic region. Founded in 2007, this physician-owned and managed company provides high-quality, cost-effective integrated medical services across the full continuum of care in hospitals and post-acute facilities. Its unique integrated staffing model, unwavering commitment to client satisfaction, and focus on improving patient outcomes, make possible real opportunities to transform care and drive value for its clients.

OTHER WHITEPAPERS
news image

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More
news image

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

Read More
news image

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

Read More
news image

Gene, Cell, & RNA Therapy Landscape

whitePaper | January 24, 2022

The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization.

Read More
news image

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Read More

State of the Global Biotech Landscape

whitePaper | November 22, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period encompasses a unique timeframe including the global COVID-19 pandemic.

Read More

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

Read More

Further Discussion on Plasmids to Establish Release Specifications Using a Risk-Based Approach to Manage Supply

whitePaper | December 6, 2022

BioPhorum’s mission is to create environments where the global biopharmaceutical industry can collaborate and accelerate its rate of progress, for the benefit of all.

Read More

Gene, Cell, & RNA Therapy Landscape

whitePaper | January 24, 2022

The American Society of Gene & Cell Therapy (ASGCT) is the primary professional membership organization.

Read More

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased
dramatically in recent years, fueled by a surge in the
clinical development of next-generation cell and gene
therapy products and more recently by the success of
COVID-19 vaccines.

Read More
More Whitepapers

Spotlight

Adfinitas Health

Adfinitas Health (formerly MDICS) is the trusted partner of more than 50 healthcare systems, hospitals, and post-acute care centers in the Mid-Atlantic region. Founded in 2007, this physician-owned and managed company provides high-quality, cost-effective integrated medical services across the full continuum of care in hospitals and post-acute facilities. Its unique integrated staffing model, unwavering commitment to client satisfaction, and focus on improving patient outcomes, make possible real opportunities to transform care and drive value for its clients.

Events